NEPH
NEPHROS INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$3.68
+0.82%Year over year
Reported trailing growth
- Revenue
- +24.2%
- EBITDA
- +21.2%
- EBIT
- +22.8%
- EPS
- +28.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +19.1%
- EBITDA
- +82.0%
- EPS
- +41.0%
Three-year CAGR
- Revenue
- +23.5%
- EBITDA
- +493.0%
- EBIT
- —
- Net income
- +1513.5%
- EPS
- +1471.4%
- Free cash flow
- +47.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026